Interval Cancer Rate and Diagnostic Performance of Fecal Immunochemical Test According to Family History of Colorectal Cancer

被引:1
|
作者
Jung, Yoon Suk [1 ]
Lee, Jinhee [2 ]
Lee, Hye Ah [3 ]
Moon, Chang Mo [4 ,5 ]
机构
[1] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Gastroenterol,Sch Med, Seoul 03181, South Korea
[2] Ajou Univ, Dept Endocrinol & Metab, Sch Med, Suwon 16499, South Korea
[3] Ewha Womans Univ, Clin Trial Ctr, Mokdong Hosp, Seoul 07985, South Korea
[4] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul 07985, South Korea
[5] Ewha Womans Univ, Coll Med, Inflammat Canc Microenvironm Res Ctr, Seoul 07985, South Korea
基金
新加坡国家研究基金会;
关键词
family history of colorectal cancer; fecal immunochemical test; colorectal cancer; RISK; INDIVIDUALS; COLONOSCOPY;
D O I
10.3390/jcm9103302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The potential role of the fecal immunochemical test (FIT) in individuals with a family history of colorectal cancer (CRC) remains unclear. We assessed interval cancer rate (ICR) after the FIT and FIT diagnostic performance according to family history of CRC. Methods: Using the Korean National Cancer Screening Program Database, we collected data on subjects who underwent the FIT between 2009 and 2011. The interval cancer rate (ICR) was defined as the number of subjects diagnosed with CRC within 1 year after the FIT per 1000 subjects with negative FIT results. Results: Of 5,643,438 subjects, 224,178 (3.97%) had a family history of CRC. FIT positivity rate (6.4% vs. 5.9%; adjusted relative risk (aRR) 1.11; 95% confidence interval (CI) 1.09-1.13) and ICR (1.4 vs. 1.1; aRR 1.43 (95% CI 1.27-1.60)) were higher in these subjects than in those with no such history. These results were the same regardless of whether subjects had undergone colonoscopy within the last 5 years before the FIT. However, the diagnostic performance of the FIT for CRC, as measured using the area under the operating characteristic curve, was similar between subjects without a family history and those with one (85.5% and 84.6%, respectively; p = 0.259). Conclusion: the FIT was 1.4 times more likely to miss CRC in subjects with a family history than in those without (aRR 1.43 for ICR), although its diagnostic performance was similar between the two groups. Our results suggest that for individuals with a family history of CRC, colonoscopy should be preferred over FIT for both screening and surveillance.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [21] Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening
    Chen, Juan
    Lin, Jie
    Zhang, Lijing
    Chen, Mengshi
    Yu, Xunbin
    Wu, Yijuan
    Wang, Tao
    Xu, Rongrong
    Tian, Tian
    Sun, Aijuan
    Zhang, Tiantian
    Lu, Yan
    Ba, Zhaofen
    Cheng, Xiaowei
    Chen, Minghong
    CLINICAL LABORATORY, 2022, 68 (12) : 2446 - 2453
  • [22] Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening
    Chen, Juan
    Lin, Jie
    Zhang, Lijing
    Chen, Mengshi
    Yu, Xunbin
    Wu, Yijuan
    Wang, Tao
    Xu, Rongrong
    Tian, Tian
    Sun, Aijuan
    Zhang, Tiantian
    Lu, Yan
    Ba, Zhaofen
    Cheng, Xiaowei
    Chen, Minghong
    CLINICAL LABORATORY, 2022, : 2446 - 2453
  • [23] Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening A Diagnostic Test Accuracy Study
    de Klaver, Willemijn
    Wisse, Pieter H. A.
    van Wifferen, Francine
    Bosch, Linda J. W.
    Jimenez, Connie R.
    van der Hulst, Rene W. M.
    Fijneman, Remond J. A.
    Kuipers, Ernst J.
    Greuter, Marjolein J. E.
    Carvalho, Beatriz
    Spaander, Manon C. W.
    Dekker, Evelien
    Coupe, Veerle M. H.
    de Wit, Meike
    Meijer, Gerrit A.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (09) : 1224 - +
  • [24] Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death
    Doubeni, Chyke A.
    Corley, Douglas A.
    Jensen, Christopher D.
    Levin, Theodore R.
    Ghai, Nirupa R.
    Cannavale, Kimberly
    Zhao, Wei K.
    Selby, Kevin
    Buckner-Petty, Skye
    Zauber, Ann G.
    Fletcher, Robert H.
    Weiss, Noel S.
    Schottinger, Joanne E.
    JAMA NETWORK OPEN, 2024, 7 (07) : e2423671
  • [25] Fecal Immunochemical Tests for Colorectal Cancer Screening
    Daly, Jeanette
    AMERICAN JOURNAL OF NURSING, 2012, 112 (10) : 67 - 69
  • [26] Fecal immunochemical test for hemoglobin in combination with fecal transferrin in colorectal cancer screening
    Gies, Anton
    Cuk, Katarina
    Schrotz-King, Petra
    Brenner, Hermann
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (08) : 1223 - 1231
  • [27] Diagnostic performance of flexible sigmoidoscopy combined with fecal immunochemical test in colorectal cancer screening: meta-analysis and modeling
    Tobias Niedermaier
    Korbinian Weigl
    Michael Hoffmeister
    Hermann Brenner
    European Journal of Epidemiology, 2017, 32 : 481 - 493
  • [28] A large proportion of fecal immunochemical test-positive participants in colorectal cancer screening is symptomatic
    de Klerk, Clasine M.
    van der Vlugt, Manon
    Bossuyt, Patrick M.
    Dekker, Evelien
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (03) : 471 - 479
  • [29] ASSOCIATION OF COLORECTAL CANCER RISK WITH CUMULATIVE FECAL IMMUNOCHEMICAL TEST VERSUS COLONOSCOPY
    Kim, Hyun-Soo
    Kim, Soo Young
    Kim, Yoon Tae
    Kim, Soon Jung
    Ahn, Su Jin
    Park, Geunu
    Park, So Hee
    Cha, Jae Myung
    Kim, Joo Sung
    Kim, Won Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 209 - 209
  • [30] Comparison between the Effectiveness Fecal Immunochemical Test and Colonoscopy As A Tool For Colorectal Cancer Early Detection
    Andila, Yossi
    Rudiman, Reno
    Purnama, Andriana
    MAJALAH KEDOKTERAN BANDUNG, 2022, 54 (01): : 51 - 56